|
1
|
Nakamoto Y and Kaneko S: Dendritic
cell-based immunotherapy for hepatocellular carcinoma. Gan To
Kagaku Ryoho. 37:413–416. 2010.(In Japanese).
|
|
2
|
Cohen S, Haimovich J and Hollander N:
Dendritic cell-based therapeutic vaccination against myeloma:
vaccine formulation determines efficacy against light chain
myeloma. J Immunol. 182:1667–1673. 2009. View Article : Google Scholar
|
|
3
|
Di Nicola M, Carlo-Stella C, Anichini A,
et al: Clinical protocol. Immunization of patients with malignant
melanoma with autologous CD34+ cell-derived dendritic
cells transduced ex vivo with a recombinant replication-deficient
vaccinia vector encoding the human tyrosinase gene: a phase I
trial. Hum Gene Ther. 14:1347–1360. 2003.PubMed/NCBI
|
|
4
|
Dubsky P, Ueno H, Piqueras B, et al: Human
dendritic cell subsets for vaccination (Review). J Clin Immunol.
25:551–572. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cao DY, Yang JY, Dou KF, Ma LY and Teng
ZH: α-fetoprotein and interleukin-18 gene-modified dendritic cells
effectively stimulate specific type-1 CD4- and CD8-mediated T-cell
response from hepatocellular carcinoma patients in vitro. Hum
Immunol. 68:334–341. 2007.
|
|
6
|
Lapteva N, Aldrich M, Weksberg D, et al:
Targeting the intratumoral dendritic cells by the oncolytic
adenoviral vaccine expressing RANTES elicits potent antitumor
immunity. J Immunother. 32:145–156. 2009. View Article : Google Scholar
|
|
7
|
Chen L, Tang XD, Yu ST, et al: Induction
of anti-tumour immunity by dendritic cells transduced with hTERT
recombinant adenovirus in mice. J Pathol. 217:685–692. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Buchsel PC and DeMeyer ES: Dendritic
cells: Emerging roles in tumor immunotherapy (Review). Clin J Oncol
Nurs. 10:629–640. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Butterfield LH, Ribas A, Potter DM and
Economou JS: Spontaneous and vaccine induced AFP-specific T cell
phenotypes in subjects with AFP-positive hepatocellular cancer.
Cancer Immunol Immunother. 56:1931–1943. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Evdokimova VN and Butterfield LH:
Alpha-fetoprotein and other tumour associated antigens for
immunotherapy of hepatocellular cancer (Review). Expert Opin Biol
Ther. 8:325–336. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gardini A, Ercolani G, Riccobon A, et al:
Adjuvant, adoptive immunotherapy with tumor infiltrating
lymphocytes plus interleukin-2 after radical hepatic resection for
colorectal liver metastases: 5-year analysis. J Surg Oncol.
87:46–52. 2004.
|
|
12
|
Dillman R, Schiltz P, DePriest C, et al:
Tumor-infiltrating lymphocytes and interleukin-2: dose and
schedules of administration in the treatment of metastatic cancer.
Cancer Biother Radiopharm. 19:730–737. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xian J, Yang H, Lin Y and Liu S:
Combination nonviral murine interleukin 2 and interleukin 12 gene
therapy and radiotherapy for head and neck squamous cell carcinoma.
Arch Otolaryngol Head Neck Surg. 131:1079–1085. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bray D, Yu SZ, Koprowski H II, Rhee J,
Kumar S, Pericle F, Suntharalingam M, Van Echo DA, Li D and
O’Malley BW Jr: Combination nonviral interleukin 2 gene therapy and
external-beam radiation therapy for head and neck cancer. Arch
Otolaryngol Head Neck Surg. 129:618–622. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li D, Zeiders JW, Liu S, Guo M, Xu Y,
Bishop JS and O’Malley BW Jr: Combination nonviral cytokine gene
therapy for head and neck cancer. Laryngoscope. 111:815–820. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kimura Y, Mizuno H, Satake K, Tahara H and
Tsukuda M: Effects of combined therapy with interleukin 2 and
interleukin 12 gene-transfected tumor vaccine for head and neck
carcinoma. Arch Otolaryngol Head Neck Surg. 129:1181–1185. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
O’Malley BW Jr, Li D, McQuone SJ and
Ralston R: Combination nonviral interleukin-2 gene immunotherapy
for head and neck cancer: from bench top to bedside. Laryngoscope.
115:391–404. 2005.PubMed/NCBI
|
|
18
|
Li D, Ronson B, Guo M, Liu S, Bishop JS,
Van Echo DA and O’Malley BW Jr: Interleukin 2 gene transfer
prevents NKG2D suppression and enhances antitumor efficacy in
combination with cisplatin for head and neck squamous cell cancer.
Cancer Res. 62:4023–4028. 2002.PubMed/NCBI
|
|
19
|
Ovali E, Dikmen T, Sonmez M, Yilmaz M,
Unal A, Dalbasti T, et al: Active immunotherapy for cancer patients
using tumor lysate pulsed dendritic cell vaccine: a safety study. J
Exp Clin Cancer Res. 26:209–214. 2007.PubMed/NCBI
|
|
20
|
Figdor CG, de Vries IJ, Lesterhuis WJ and
Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat Med.
10:475–480. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Koya RC, Weber JS, Kasahara N, et al:
Making dendritic cells from the inside out: Lentiviral
vector-mediated gene delivery of granulocyte-macrophage
colony-stimulating factor and interleukin 4 into CD14+
monocytes generates dendritic cells in vitro. Hum Gene Ther.
15:733–748. 2004. View Article : Google Scholar
|
|
22
|
Liu Y, Chiriva-Internati M, Grizzi F, et
al: Rapid induction of cytotoxic T-cell response against cervical
cancer cells by human papillomavirus type 16 E6 antigen gene
delivery into human dendritic cells by an adeno-associated virus
vector. Cancer Gene Ther. 8:948–957. 2001. View Article : Google Scholar
|
|
23
|
Asemissen AM and Brossart P: Vaccination
strategies in patients with renal cell carcinoma. Cancer Immunol
Immunother. 58:1169–1174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Timares L, Douglas JT, Tillman BW, et al:
Adenovirus-mediated gene delivery to dendritic cells. Methods Mol
Biol. 246:139–154. 2004.PubMed/NCBI
|
|
25
|
Chiriva-Internati M, Liu Y, Salati E, et
al: Efficient generation of cytotoxic T lymphocytes against
cervical cancer cells by adeno-associated virus/human
papillomavirus type 16 E7 antigen gene transduction into dendritic
cells. Eur J Immunol. 32:30–38. 2002. View Article : Google Scholar
|
|
26
|
Motta I, André F, Lim A, et al:
Cross-presentation by dendritic cells of tumor antigen expressed in
apoptotic recombinant canarypox virus-infected dendritic cells. J
Immunol. 167:1795–1802. 2001. View Article : Google Scholar
|
|
27
|
Diebold SS, Cotton M, Koch N and Zenke M:
MHC class II presentation of endogenously expressed antigens by
transfected dendritic cells. Gene Ther. 8:487–493. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moll H: Antigen delivery by dendritic
cells (Review). Int J Med Microbiol. 294:337–344. 2004. View Article : Google Scholar
|
|
29
|
Alisa A, Ives A, Pathan AA, et al:
Analysis of CD4+ T-cell responses to a novel
alpha-fetoprotein-derived epitope in hepatocellular carcinoma
patients. Clin Cancer Res. 11:686–6694. 2005.
|
|
30
|
Mizukoshi E, Nakamoto Y, Tsuji H, et al:
Identification of alpha-fetoprotein-derived peptides recognized by
cytotoxic T lymphocytes in HLA-A24+ patients with
hepatocellular carcinoma. Int J Cancer. 118:1194–1204. 2006.
View Article : Google Scholar : PubMed/NCBI
|
